Jaguar Health, Inc. Stock News

Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea (CID). The trial inc

(PR-inside.com) Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2 HALT-D trial evaluating crofelemer for the prevention of chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane.1 These therapies are known to cause CID in up to 80% of breast cancer patients, reaching grade 3 (requiring hospitalization) in 8-12% of patients.2-5 CID can have a negative impact on quality of life, particularly when it persists through much of the course of ..

Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medicationSAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2021 Results - Earnings Call Transcript

Jaguar Health (NASDAQ:JAGX) reported its Q3 earnings results on Wednesday, November 17, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcastSAN FRANCISCO,

Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Wednesday, 2021-11-17. Here's what investors need to know before the announcement.

Click here to register for webcastCompany plans to file Q3 2021 10-Q on November 17, 2021SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that

(PR-inside.com) Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company''s investor webcast to review third-quarter 2021 financials and provide business updates will take place at 8:30 a.m. Eastern Time on Wednesday, November 17, 2021 instead of today. The date change is due to the need for additional time to finalize accounting-related aspects of the recently closed merger of Dragon SPAC S.p.A. and Napo EU S.p.A., Jaguar''s majority owned Italian subsidiary. Participation Instructions for Webcast When: Wednesday, November 17, ..

Zacks Investment Research upgraded shares of Jaguar Health (NASDAQ:JAGX) from a hold rating to a buy rating in a research report released on Friday, Zacks.com reports. Zacks Investment Research currently has $2.00 price objective on the biotechnology companys stock. According to Zacks, Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and []

Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that t

Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.

Click here to register for webcast Company plans to file Q3 2021 10-Q on November 15, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that c

Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2